Tech Company Financing Transactions
Moat Biotechnology Funding Round
Moat Biotechnology closed a $6.5 million venture capital round on 6/13/2023. Backers included Cortado Ventures and Boyd Street Ventures.
Transaction Overview
Company Name
Announced On
6/13/2023
Transaction Type
Venture Equity
Amount
$6,500,000
Round
Undisclosed
Investors
Cortado Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand the ongoing Phase 1 clinical trial of an intranasal or inhaled vaccine boost for COVID-19 and initiate the development of 2nd and 3rd SC-AdVax vaccines for additional mucosal pathogens.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
840 Research Parkway 516
Oklahoma City, OK 73104
USA
Oklahoma City, OK 73104
USA
Phone
Undisclosed
Email Address
Overview
Developer of oral vaccines designed to accelerate the treatment of infectious diseases. The company holds an exclusive patent license for the novel second-generation single-cycle adenovirus vaccine platform to develop intranasal and oral vaccines that can elicit and boost both mucosal and systemic immunity for the treatment of viruses and infectious diseases, enabling patients with significantly advanced treatment over existing and traditional vaccines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Rollins
Browse more venture capital transactions:
Prev: 6/13/2023: Climate Vault Solutions venture capital transaction
Next: 6/13/2023: Indifi Technologies venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here come from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs